Relative Biological Effectiveness (RBE) of 131 I Radiation Relative to 60 Co Gamma Rays

Objective: To assess relative biological effectiveness (RBE) of 131 I radiation relative to 60 Co gamma rays in glioblastoma spheroid cells. Materials and Methods: In this experimental study, glioblastoma spheroid cells were exposed to 131 I radiation and 60 Co gamma rays. Radiation induced DNA damage was evaluated by alkaline comet assay. Samples of spheroid cells were treated by radiation from 131 I for four different periods of time to find the dose-response equation. Spheroid cells were also exposed by 200 cGy of 60 Co gamma rays as reference radiation to induce DNA damage as endpoint. Results: Resulted RBE of 131 I radiation relative to 60 Co gamma rays in 100 µm giloblastoma spheroid cells was equal to 1.16. Conclusion: The finding of this study suggests that 131 I photons and electrons can be more effective than 60 Co gamma rays to produce DNA damage in glioblastoma spheroid cells.

[1]  A. Pitman,et al.  I-131 MIBG THERAPY FOR ADVANCED STAGE III & IV NEUROBLASTOMA , 2011 .

[2]  Megan K. Lessig.  The Role of 131I-MIBG in High-Risk Neuroblastoma Treatment , 2009, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.

[3]  Colin R Muirhead,et al.  Review of relative biological effectiveness dependence on linear energy transfer for low-LET radiations , 2009, Journal of radiological protection : official journal of the Society for Radiological Protection.

[4]  Yong Zhao,et al.  The biological effect of 125I seed continuous low dose rate irradiation in CL187 cells , 2009, Journal of experimental & clinical cancer research : CR.

[5]  H. Lundqvist,et al.  Cross-fire doses from β-emitting radionuclides in targeted radiotherapy. A theoretical study based on experimentally measured tumor characteristics , 2008, Physics in medicine and biology.

[6]  Jing Xu,et al.  Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. , 2006, International journal of radiation oncology, biology, physics.

[7]  P. Unak,et al.  Absorbed dose estimates at the cellular level for 131I. , 2005, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[8]  A. Collins,et al.  The comet assay for DNA damage and repair , 2004, Molecular biotechnology.

[9]  J. Norton,et al.  High‐dose 131I‐metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma , 2003, Cancer.

[10]  S. Hundahl.  Perspective: National Cancer Institute summary report about estimated exposures and thyroid doses received from iodine 131 in fallout after Nevada atmospheric nuclear bomb tests , 1998, CA: a cancer journal for clinicians.

[11]  P. Olive,et al.  Multicell spheroid response to drugs predicted with the comet assay. , 1997, Cancer research.

[12]  T. Straume,et al.  High-energy gamma rays in Hiroshima and Nagasaki: implications for risk and WR. , 1995, Health physics.

[13]  J Vennart,et al.  1990 Recommendations of the International Commission on Radiological Protection. , 1991, Annals of the ICRP.

[14]  P. Riva,et al.  Glioblastoma therapy by direct intralesional administration of I-131 radioiodine labeled antitenascin antibodies , 2007, Cell Biophysics.

[15]  J. Valentin.  The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. , 2007, Annals of the ICRP.

[16]  Relative biological effectiveness (RBE), quality factor (Q), and radiation weighting factor (w(R)). A report of the International Commission on Radiological Protection. , 2003, Annals of the ICRP.